Clinical trials on sunitinib, pazopanib, and famitinib also suggest that these VEGFR inhibitors have therapeutic advantages in heavily chemotherapy-pretreated patients with R/M NPC. The gene discussed is KDR; the disease is nasopharyngeal carcinoma.